Targeting Epstein-Brr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing
スポンサーリンク
概要
著者
-
Moss D
Tumour Immunology Laboratory Epstein-barr Virus Unit Queensland Institute Of Medical Research And Un
-
Khanna Rajiv
Tumour Immunology Laboratory Epstein-barr Virus Unit Queensland Institute Of Medical Research And Un
-
Cooper Leanne
Tumour Immunology Laboratory Epstein-barr Virus Unit Queensland Institute Of Medical Research And Un
-
KHANNA Rajiv
Queensland Institute of Medical Research, The Bancroft Centre
-
BURROWS Scott
Queensland Institute of Medical Research, The Bancroft Centre
-
STEIGERWALD-MULLEN Patty
Department of Pathology and Microbiology, University of Virginia
-
MOSS Denis
Queensland Institute of Medical Research, The Bancroft Centre
-
KURILLA Michael
Department of Pathology and Microbiology, University of Virginia
-
COOPER Leanne
Queensland Institute of Medical Research, The Bancroft Centre
-
Burrows Scott
Queensland Institute Of Medical Research The Bancroft Centre
-
Kurilla Michael
Department Of Pathology And Microbiology University Of Virginia
-
Steigerwald-mullen Patty
Department Of Pathology And Microbiology University Of Virginia
関連論文
- Immunization with tumor-associated epitopes fused to an endoplasmic reticulum translocation signal sequence affords protection against tumors with down-regulated expression of MHC and peptide transporters
- Targeting Epstein-Brr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing